Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography

Xenobiotica

Volumn 43, Issue 5, 2013, Pages 461-467

  Ekdahl, Anja ^a   Aurell Holmberg, Ann ^a   Castagnoli, Neal ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Drug evaluation; Gastroesophageal reflux; Mass spectrometry; Metabolites; Preclinical

Indexed keywords

CARBON 14; DRUG METABOLITE; LESOGABERAN; PHOSPHINIC ACID DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; DRUG LABELING; DRUG METABOLISM; DRUG STRUCTURE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; ION TRAP MASS SPECTROMETRY; MALE; NONHUMAN; RADIOCHEMISTRY; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STANDARD; TANDEM MASS SPECTROMETRY; URINE;

EID: 84875869973     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.725486     Document Type: Article

References (22)

1. Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, Silberg DG, Sifrim D. (2010a). Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139: 409-417.
2. Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. (2010b). Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 31: 1208-1217.
3. Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M, Denison H. (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: A randomised placebo-controlled trial. Gut 60: 1182-1188.
4. Chirita RI, West C, Finaru AL, Elfakir C. (2010). Approach to hydrophilic interaction chromatography column selection: Application to neurotransmitters analysis. J Chromatogr A 1217: 3091-3104.
5. Cioffi U, Rosso L, De Simone M. (1999). Gastroesophageal reflux disease. Pathogenesis, symptoms and complications. Minerva Gastroenterol Dietol 45: 43-49.
6. Clift MD, Ji H, Deniau GP, O'Hagan D, Silverman RB. (2007). Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for γ-aminobutyric acid aminotransferase. Conformational probes for GABA binding. Biochemistry 46: 13819-13828. (Pubitemid 350223909)
7. Cooke BR, Bligh SW, Cybulski ZR, Ioannides C, Hall M. (2012). Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes. Drug Metab Dispos 40: 70-75.
8. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22: 357-368.
9. Dejaegher B, Vander Heyden Y. (2010). HILIC methods in pharmaceutical analysis. J Sep Sci 33: 698-715.
10. Dent J, El-Serag HB, Wallander MA, Johansson S. (2005). Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 54: 710-717. (Pubitemid 40559260)
11. El-Serag H, Becher A, Jones R. (2010). Systematic review: Persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 32: 720-737.
12. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11: 678-685.
13. FDA. (2008). Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA- 2008-D-0065-GDL.pdf. Accessed on: 5 March 2012.
14. Fountain KJ, Xu J, Diehl DM, Morrison D. (2010). Influence of stationary phase chemistry and mobile-phase composition on retention, selectivity, and MS response in hydrophilic interaction chromatography. J Sep Sci 33: 740-751.
15. Hsieh Y. (2010). Hydrophilic interaction liquid chromatographytandem mass spectrometry for drug development. Curr Drug Discov Technol 7: 223-231.
16. Humm A, Fritsche E, Steinbacher S, Huber R. (1997). Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: A mitochondrial enzyme involved in creatine biosynthesis. EMBO J 16: 3373-3385. (Pubitemid 27250033)
17. Ikegami T, Tomomatsu K, Takubo H, Horie K, Tanaka N. (2008). Separation efficiencies in hydrophilic interaction chromatography. J Chromatogr A 1184: 474-503.
18. Jian W, Xu Y, Edom RW, Weng N. (2011). Analysis of polar metabolites by hydrophilic interaction chromatography-MS/MS. Bioanalysis 3: 899-912.
19. Niazi M, Skrtic S, Ruth M, Holmberg AA. (2011). Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: A novel GABA(B)-receptor agonist reflux inhibitor. Drugs R D 11: 77-83.
20. Smith DA, Obach RS. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22: 267-279.
21. Sun J, Dahan A, Amidon GL. (2010). Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach. J Med Chem 53: 624-632.
22. Walker JB. (1979). Creatine: Biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol 50: 177-242.